Home Stock

Stock Research: DongKook Pharmaceutical

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

DongKook Pharmaceutical

KOE:086450 KR7086450004
97
  • Value
    60
  • Growth
    73
  • Safety
    Safety
    88
  • Combined
    89
  • Sentiment
    92
  • 360° View
    360° View
    97
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

DongKook Pharmaceutical Co., Ltd. is a Korea-based company engaged in the development, manufacture, and distribution of pharmaceuticals. It operates in the pharmaceutical industry, providing remedies for oral troubles, skin troubles, gynecology diseases, contrast mediums, anesthetics, anticancer medicines, circulatory system agents, arthritis and pancreatitis remedies, antiphlogistic, anodynes, antibiotics, vitamins, and raw materials for pharmaceuticals, along with a rental business. The company distributes its products domestically and to overseas markets including Japan, Germany, India, Brazil, and Mexico. In the last fiscal year, the company had a market cap of $596 millions, profits of $303 millions, and revenue of $550 millions.

more
Strongest Rank Capital Growth
Weakest Rank Pro Holdings
Country South Korea
Industry Pharmaceuticals
Size Small
Website dkpharm.co.kr
Index
DongKook Pharmaceutical stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Feb-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
60 56 66 49
Growth
73 65 57 67
Safety
Safety
88 44 61 63
Sentiment
92 96 100 82
360° View
360° View
97 86 96 89
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
89 100 97 93
Opinions Change
50 77 89 96
Pro Holdings
n/a 76 90 6
Market Pulse
n/a n/a n/a n/a
Sentiment
92 96 100 82
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
60 56 66 49
Growth
73 65 57 67
Safety Safety
88 44 61 63
Combined
89 61 75 67
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
75 78 78 61
Price vs. Earnings (P/E)
61 72 72 62
Price vs. Book (P/B)
47 38 51 34
Dividend Yield
59 37 46 32
Value
60 56 66 49
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
67 75 74 69
Profit Growth
60 60 34 23
Capital Growth
36 50 64 90
Stock Returns
75 44 35 29
Growth
73 65 57 67
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
73 43 51 46
Refinancing
65 68 67 61
Liquidity
70 25 47 59
Safety Safety
88 44 61 63

Similar Stocks

Discover high‑ranked alternatives to DongKook Pharmaceutical and broaden your portfolio horizons.

Hyundai Home Shopping Network

KSC:057050
Country: South Korea
Industry: Internet Retail
Size: Medium
Full Stock Analysis

E1

KSC:017940
Country: South Korea
Industry: Oil & Gas Transportation
Size: Medium
Full Stock Analysis

Galaxy Entertainment

HKG:27
Country: Hong Kong
Industry: Casinos & Gaming
Size: X-Large
Full Stock Analysis

Subaru

TYO:7270
Country: Japan
Industry: Automobile Manufacturers
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

This is an all-around strong stock. It shows good value, high growth, safe financing, and positive professional sentiment. It is ideal for most buy-and-hold investors who value a good all-around stock.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews